References in periodicals archive ?
Measuring Outcomes in Patients with Pulmonary Arterial Hypertension (PAH) Not on Active Treatment (MOTION): A study of the effects of riociguat on patient-reported outcomes and an exploration of telemetric technology in PAH
Data Source: Data are from CHEST-1, a trial of 261 patients with inoperable chronic thromboembolic pulmonary hypertension, and PATENT-1, a trial of 443 patients with pulmonary arterial hypertension.
Pulmonary arterial hypertension is more common in the human population than is currently realized, and unfortunately, is often fatal," said co-author Dr.
Although many agents, including serotonin, adrenomedullin, vasoactive intestinal peptide and vascular endothelial growth factor have been implicated in the pathogenesis of pulmonary arterial hypertension, prostaglandin, thromboxane, nitric oxide and endothelin have received the most attention.
Tracleer(tm) today - Approved in Pulmonary arterial hypertension Tracleer(tm), the first orally available dual endothelin receptor antagonist, is currently approved and available in the United States, the European Union (Germany and UK, others to follow), Canada and Switzerland for the treatment of Pulmonary Arterial Hypertension, a chronic life-threatening condition that severely compromises the function of the lungs and heart.
A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The analysis of Pulmonary Arterial Hypertension individual drugs sales are also provided in the report.
The incidence of pulmonary arterial hypertension in patients with systemic sclerosis is 0.
Abstract: Idiopathic pulmonary arterial hypertension is a disease involving small muscular pulmonary arteries and arterioles.
Several promising new treatments may prolong lives as well as improve the quality of life for people living with pulmonary arterial hypertension.
Texas Biotechnology also has two highly selective endothelin A receptor antagonists in clinical development for pulmonary arterial hypertension and congestive heart failure.
com/research/n92gtn/pulmonary) has announced the addition of GlobalData's new report "Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2012" to their offering.
Actelion today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for macitentan (OpsumitA) for the treatment of patients with pulmonary arterial hypertension.
PARIS -- Psoriasis is highly associated with several diseases, including arterial hypertension, type 1 and type 2 diabetes mellitus, and alcoholism--a finding with profound implications for monitoring patients and choosing medications, Ulrich Mrowietz, M.